Equities

Chemclin Diagnostics Co Ltd

688468:SHH

Chemclin Diagnostics Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)5.52
  • Today's Change-1.78 / -24.38%
  • Shares traded2.36m
  • 1 Year change-51.62%
  • Beta0.8502
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Chemclin Diagnostics Co Ltd is a China-based company mainly engaged in the research and development of clinical immuno chemiluminescence diagnostic test reagents and instruments. The Company's products are LiCA series of diagnostic reagents based on light-induced chemiluminescence and Chemclin series of diagnostic reagents and instruments based on enzymatic chemiluminescence, which are mainly used in infectious diseases (such as hepatitis B, hepatitis C, Acquired Immunodeficiency Syndrome, syphilis, hepatitis A, hepatitis E) detection of markers, tumor markers, thyroid hormones, reproductive endocrine hormones, diabetes, myocardial markers and inflammation. The Company mainly operates its businesses in the domestic market.

  • Revenue in CNY (TTM)443.86m
  • Net income in CNY139.29m
  • Incorporated2007
  • Employees731.00
  • Location
    Chemclin Diagnostics Co LtdNo. 7 Fengxian M. Road, Haidian DistrictBEIJING 100094ChinaCHN
  • Phone+86 1 058717511
  • Fax+86 1 058717501
  • Websitehttp://www.chemclin.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jiangsu Cowin Biotech Co Ltd118.17m-144.51m2.59bn657.00--1.69--21.93-1.30-1.301.0613.630.06671.321.43179,863.40-8.45---8.93--53.54---126.60--13.60--0.0214---67.15---153.00------
Nanjing Medlander Medical Tech Co Ltd380.95m101.15m2.60bn481.0025.351.98--6.811.021.023.8613.100.25271.9821.47791,989.407.06--7.76--71.46--27.94--7.57--0.0115---9.57---26.19------
Beijing Hotgen Biotech Co Ltd520.50m-67.64m2.80bn1.04k--0.8585--5.38-0.7349-0.73495.7435.250.14842.205.85502,410.60-2.1329.65-2.2234.7046.9856.08-14.3332.268.95--0.002641.92-84.7823.67-97.10-10.6757.98--
Chemclin Diagnostics Co Ltd443.86m139.29m2.93bn731.0021.002.09--6.600.34760.34761.113.490.24911.0016.34607,195.307.8211.018.7312.3274.8974.1931.3831.075.16--0.151536.64-4.284.00-3.44--44.10--
Nanjing Vishee Medical Technology Co Ltd422.21m112.74m2.96bn700.0026.161.84--7.011.181.184.4216.830.24013.1212.37603,153.406.4110.276.9211.4370.2173.2626.7033.998.31--0.000347.5743.7217.3445.2216.5526.69--
Beijing Succeeder Technology Inc297.74m112.75m3.03bn296.0026.951.85--10.181.061.062.8015.410.17662.518.661,005,870.006.697.777.028.2560.3961.0337.8538.3414.78--0.0000422.2220.406.6012.2915.5799.03--
Cowealth Medical China Co Ltd970.41m29.67m3.04bn240.00102.392.60--3.130.07450.07452.442.930.64353.901.254,043,355.002.015.802.598.0919.6220.743.136.143.65--0.082923.89-14.623.85-42.96-6.7532.85--
Hangzhou Biotest Biotech Co Ltd518.65m104.29m3.21bn629.0030.401.35--6.190.98970.98974.9422.270.2042.616.85824,563.604.0129.454.2333.3052.4256.8319.6441.5912.53--0.000329.32-76.7519.65-86.2241.3334.82--
Data as of Sep 13 2024. Currency figures normalised to Chemclin Diagnostics Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

2.36%Per cent of shares held by top holders
HolderShares% Held
Yinhua Fund Management Co., Ltd.as of 30 Jun 20243.58m1.30%
China Asset Management Co., Ltd.as of 30 Jun 20241.37m0.50%
Maxwealth Fund Management Co., Ltd.as of 30 Jun 2024537.20k0.20%
Bank of Communications Schroder Fund Management Co., Ltd.as of 30 Jun 2024231.10k0.08%
Baoying Fund Management Co., Ltd.as of 30 Jun 2024198.00k0.07%
Penghua Fund Management Co., Ltd.as of 30 Jun 2024129.28k0.05%
Essence Fund Co., Ltd.as of 30 Jun 2024126.52k0.05%
Hui'an Fund Management Co. Ltd.as of 30 Jun 2024115.55k0.04%
GF Fund Management Co., Ltd.as of 30 Jun 2024108.70k0.04%
Morgan Stanley Huaxin Fund Management Co., Ltd.as of 30 Jun 2024101.20k0.04%
More ▼
Data from 30 Jun 2024 - 27 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.